A phase 2 clinical trial assessing taperprumig, a novel targeted therapy, in patients with granulomatosis with polyangiitis (GPA) and microscopic polyangiitis (MPA). The study evaluates safety, efficacy, and its potential to reduce glucocorticoid exposure, with...
